These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33468668)

  • 21. Unique mutations of the cystic fibrosis transmembrane conductance regulator gene of three cases of cystic fibrosis in Nagasaki, Japan.
    Izumikawa K; Tomiyama Y; Ishimoto H; Sakamoto N; Imamura Y; Seki M; Sawai T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Yoshimura K; Kohno S
    Intern Med; 2009; 48(15):1327-31. PubMed ID: 19652440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
    Zielenski J; Bozon D; Kerem B; Markiewicz D; Durie P; Rommens JM; Tsui LC
    Genomics; 1991 May; 10(1):229-35. PubMed ID: 1710599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combined analysis of the cystic fibrosis transmembrane conductance regulator: implications for structure and disease models.
    Chen JM; Cutler C; Jacques C; Boeuf G; Denamur E; Lecointre G; Mercier B; Cramb G; Férec C
    Mol Biol Evol; 2001 Sep; 18(9):1771-88. PubMed ID: 11504857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants.
    Mutesa L; Azad AK; Verhaeghe C; Segers K; Vanbellinghen JF; Ngendahayo L; Rusingiza EK; Mutwa PR; Rulisa S; Koulischer L; Cassiman JJ; Cuppens H; Bours V
    Chest; 2009 May; 135(5):1233-1242. PubMed ID: 19017867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene?
    Dorfman R; Nalpathamkalam T; Taylor C; Gonska T; Keenan K; Yuan XW; Corey M; Tsui LC; Zielenski J; Durie P
    Clin Genet; 2010 May; 77(5):464-73. PubMed ID: 20059485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel missense mutation A1081P in the cystic fibrosis transmembrane conductance regulator (CFTR) gene identified in a Laotian patient with congenital bilateral absence of the vas deferens.
    Ngukam A; Jacquemont ML; Souville I; Viel M; Beldjord C; Hubert D; Hughes JN; Bienvenu T
    J Trop Pediatr; 2004 Aug; 50(4):239-40. PubMed ID: 15357566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis.
    Gisler FM; von Kanel T; Kraemer R; Schaller A; Gallati S
    Eur J Hum Genet; 2013 Apr; 21(4):397-403. PubMed ID: 22892532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.
    Xue X; Mutyam V; Thakerar A; Mobley J; Bridges RJ; Rowe SM; Keeling KM; Bedwell DM
    Hum Mol Genet; 2017 Aug; 26(16):3116-3129. PubMed ID: 28575328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers.
    Sharma H; Mavuduru RS; Singh SK; Prasad R
    Mol Hum Reprod; 2014 Sep; 20(9):827-35. PubMed ID: 24958810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor.
    Krainer G; Schenkel M; Hartmann A; Ravamehr-Lake D; Deber CM; Schlierf M
    J Biol Chem; 2020 Feb; 295(7):1985-1991. PubMed ID: 31882543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2.
    Gregory RJ; Rich DP; Cheng SH; Souza DW; Paul S; Manavalan P; Anderson MP; Welsh MJ; Smith AE
    Mol Cell Biol; 1991 Aug; 11(8):3886-93. PubMed ID: 1712898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency and clinical significance of the S1235R mutation in the cystic fibrosis transmembrane conductance regulator gene: results from a collaborative study.
    Monaghan KG; Feldman GL; Barbarotto GM; Manji S; Desai TK; Snow K
    Am J Med Genet; 2000 Dec; 95(4):361-5. PubMed ID: 11186891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease-relevant mutations alter amino acid co-evolution networks in the second nucleotide binding domain of CFTR.
    Ivey G; Youker RT
    PLoS One; 2020; 15(1):e0227668. PubMed ID: 31978131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between CFTR and CTRC variants and the clinical phenotype in late-onset cystic fibrosis disease with chronic pancreatitis.
    Tomaiuolo AC; Sofia VM; Surace C; Majo F; Genovese S; Petrocchi S; Grotta S; Alghisi F; Lucidi V; Angioni A
    J Mol Diagn; 2015 Mar; 17(2):171-8. PubMed ID: 25636364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
    Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CFTR allelic heterogeneity in Mexican patients with cystic fibrosis: implications for molecular screening.
    Chávez-Saldaña M; Yokoyama E; Lezana JL; Carnevale A; Macías M; Vigueras RM; López M; Orozco L
    Rev Invest Clin; 2010; 62(6):546-52. PubMed ID: 21416780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations.
    Dörk T; Fislage R; Neumann T; Wulf B; Tümmler B
    Hum Genet; 1994 Jan; 93(1):67-73. PubMed ID: 7505767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.